A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients
 with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Inclusion Criteria:

 -  Adult male or female aged 18-55 years inclusive at screening

 -  Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis

 Exclusion Criteria:

 -  Multiple Sclerosis course other than relapsing-remitting multiple sclerosis

 -  History of malignancy

 -  History of clinically significant chronic disease of the immune system (other than
 Multiple Sclerosis)

 -  Inability to undergo Gd-enhanced MRI scans

 -  Diagnosis of diabetes mellitus (type I or type II)